Ocugen said it will move its gene therapy for geographic atrophy (GA) into Phase 3 after mixed results in a prior, smaller study. The company’s decision reflects an attempt to convert earlier retinal data into a larger confirmatory trial program in a segment where endpoint clarity and patient selection can drive pivotal success or failure. Investor response to the pathway decision remained cautious in the market, with coverage noting that outcomes did not fully meet expectations relative to earlier signals. For developers in ophthalmology, the Phase 3 step is a high-stakes inflection point that typically determines filing timing and competitive positioning in complement- and cell-based treatment spaces.